Induced pluripotent stem cell-based therapies for organ fibrosis

Wei Cheng; Wei Cheng; Chengming Fan; Qing Song; Qing Song; Ping Chen; Ping Chen; Hong Peng; Hong Peng; Ling Lin; Ling Lin; Cong Liu; Cong Liu; Bin Wang; Zijing Zhou; Zijing Zhou

doi:10.3389/fbioe.2023.1119606

Frontiers in Bioengineering and Biotechnology (May 2023)

Induced pluripotent stem cell-based therapies for organ fibrosis

Wei Cheng,
Wei Cheng,
Chengming Fan,
Qing Song,
Qing Song,
Ping Chen,
Ping Chen,
Hong Peng,
Hong Peng,
Ling Lin,
Ling Lin,
Cong Liu,
Cong Liu,
Bin Wang,
Zijing Zhou,
Zijing Zhou

Affiliations

Wei Cheng: Department of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha, China
Wei Cheng: Research Unit of Respiratory Disease, Central South University, Changsha, China
Chengming Fan: Department of Cardiovascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China
Qing Song: Department of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha, China
Qing Song: Research Unit of Respiratory Disease, Central South University, Changsha, China
Ping Chen: Department of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha, China
Ping Chen: Research Unit of Respiratory Disease, Central South University, Changsha, China
Hong Peng: Department of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha, China
Hong Peng: Research Unit of Respiratory Disease, Central South University, Changsha, China
Ling Lin: Department of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha, China
Ling Lin: Research Unit of Respiratory Disease, Central South University, Changsha, China
Cong Liu: Department of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha, China
Cong Liu: Research Unit of Respiratory Disease, Central South University, Changsha, China
Bin Wang: Department of Thoracic Surgery, Second Xiangya Hospital, Central South University, Changsha, China
Zijing Zhou: Department of Pulmonary and Critical Care Medicine, Second Xiangya Hospital, Central South University, Changsha, China
Zijing Zhou: Research Unit of Respiratory Disease, Central South University, Changsha, China

DOI: https://doi.org/10.3389/fbioe.2023.1119606
Journal volume & issue: Vol. 11

Abstract

Read online

Fibrotic diseases result in organ remodelling and dysfunctional failure and account for one-third of all deaths worldwide. There are no ideal treatments that can halt or reverse progressive organ fibrosis, moreover, organ transplantation is complicated by problems with a limited supply of donor organs and graft rejection. The development of new approaches, especially induced pluripotent stem cell (iPSC)-based therapy, is becoming a hot topic due to their ability to self-renew and differentiate into different cell types that may replace the fibrotic organs. In the past decade, studies have differentiated iPSCs into fibrosis-relevant cell types which were demonstrated to have anti-fibrotic effects that may have the potential to inform new effective precision treatments for organ-specific fibrosis. In this review, we summarize the potential of iPSC-based cellular approaches as therapeutic avenues for treating organ fibrosis, the advantages and disadvantages of iPSCs compared with other types of stem cell-based therapies, as well as the challenges and future outlook in this field.

Published in Frontiers in Bioengineering and Biotechnology

ISSN: 2296-4185 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Technology: Chemical technology: Biotechnology
Website: http://www.frontiersin.org/bioengineering_and_biotechnology

About the journal

Abstract

Keywords